These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35194364)

  • 1. Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues.
    Du G; Du W; An Y; Wang M; Hao F; Tong X; Gong Q; He X; Jiang H; He W; Zheng M; Zhang D
    Med Chem Res; 2022; 31(4):555-579. PubMed ID: 35194364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
    Paton DM
    Drugs Today (Barc); 2016 Sep; 52(9):485-493. PubMed ID: 27883115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease.
    Pflugfelder SC; Stern M; Zhang S; Shojaei A
    J Ocul Pharmacol Ther; 2017; 33(1):5-12. PubMed ID: 27906544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.
    Semba CP; Gadek TR
    Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.
    Perez VL; Pflugfelder SC; Zhang S; Shojaei A; Haque R
    Ocul Surf; 2016 Apr; 14(2):207-15. PubMed ID: 26807723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [TOPICAL ANTI-INFLAMMATORY AGENTS FOR DRY EYE DISEASE].
    Erdinest N; Solomon A
    Harefuah; 2019 Feb; 158(2):130-135. PubMed ID: 30779493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy.
    Godin MR; Gupta PK
    Clin Ophthalmol; 2017; 11():951-957. PubMed ID: 28579745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.
    Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME
    Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.
    Guimaraes de Souza R; Yu Z; Stern ME; Pflugfelder SC; de Paiva CS
    J Ocul Pharmacol Ther; 2018 Sep; 34(7):543-549. PubMed ID: 29958030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multivalent ICAM-1 Binding Nanoparticle which Inhibits ICAM-1 and LFA-1 Interaction Represents a New Tool for the Investigation of Autoimmune-Mediated Dry Eye.
    Hsueh PY; Ju Y; Vega A; Edman MC; MacKay JA; Hamm-Alvarez SF
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.
    Zhong M; Gadek TR; Bui M; Shen W; Burnier J; Barr KJ; Hanan EJ; Oslob JD; Yu CH; Zhu J; Arkin MR; Evanchik MJ; Flanagan WM; Hoch U; Hyde J; Prabhu S; Silverman JA; Wright J
    ACS Med Chem Lett; 2012 Mar; 3(3):203-6. PubMed ID: 24900456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary study of cyclosporine A/Lifitegrast subconjunctival sustained-release drug membrane in the treatment of dry eyes.
    Yang J; Chen M; Wu F; Zuo J; Ma H
    Eye Vis (Lond); 2024 Jun; 11(1):22. PubMed ID: 38872158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118).
    Sun Y; Zhang R; Gadek TR; O'Neill CA; Pearlman E
    J Ocul Pharmacol Ther; 2013 May; 29(4):395-402. PubMed ID: 23215542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of lymphocyte adhesion to cultured human corneal epithelial cells.
    Iwata M; Sawada S; Sawa M; Thoft RA
    Curr Eye Res; 1997 Aug; 16(8):751-60. PubMed ID: 9255503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry eye syndrome: developments and lifitegrast in perspective.
    Lollett IV; Galor A
    Clin Ophthalmol; 2018; 12():125-139. PubMed ID: 29391773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
    Kim CE; Kleinman HK; Sosne G; Ousler GW; Kim K; Kang S; Yang J
    Sci Rep; 2018 Jul; 8(1):10500. PubMed ID: 30002412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.